

September 1, 2011
AnGes MG, Inc.

**AnGes MG's Project Received a Support Grant by the Ministry of Economy,
Trade and Industry
- "Development and Improvement of Medical Device for Decubitus Ulcer
to Solve Infection Problem" Project -**

AnGes MG, Inc. is pleased to announce that its project named "Development and Improvement of Medical Device for Decubitus Ulcer to Solve Infection Problem" was designated by the Ministry of Economy, Trade and Industry (METI) as a project that supports the collaboration of hospitals and industry for the development of medical devices which solve issues in medical practice. AnGes MG submitted the grant proposal jointly with Morishita Jintan Co., Ltd. (hereinafter called "Morishita Jintan"), Graduate School of Medicine, Osaka University (Professor Morishita and others) and a specified nonprofit corporation, Kinki Bio-industry Development Organization.

As the population ages, nosocomial infections caused by decubitus ulcer and infections originated from decubitus ulcer are becoming social issues. Antimicrobial agents are effective against infections. However, they have recently become known to delay the wound healing and thus, the usage of antimicrobial agents for prevention of infections is becoming less. Also, there is a risk of unregulated use of antimicrobial agents leading to onset of new drug resistant bacteria in addition to already existing ones such as MRSA and drug resistant Acinetobacter, which is a serious issue in clinical settings. Therefore, there is a need for establishment of effective prevention methods of infections.

In the above mentioned project, AnGes MG plans to develop a novel wound dressing with Morishita Jintan which owns manufacturing technology of wound dressings, using "functional peptides" which was developed jointly with Osaka University.

Non-operating income is expected to be generated in year 2012. Meanwhile, this trend will have no effect on the business performance for the fiscal year of 2011.

<Reference>

Company name:	Morishita Jintan Co., Ltd.
Head office:	1-2-40 Tamatsukuri, Chuo-ku, Osaka
Representative:	Junichi Komamura, Representative Director & President
Established:	November, 1936
Capital:	3,537 million yen
Number of employees:	228
Consolidated sales:	7,732 million yen (term ending March 2011)
Scope of business:	Manufacture and distribution of medicines, quasi-medicines, medical devices, food products, etc.